Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rg-7603. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 20/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.90 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.78 |
| ▸ | RPTOR | Q8N122 | 5/20 | 0.75 |
| ▸ | MLST8 | Q9BVC4 | 5/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rg-7603 SCHEMBL25062086 | 1.00 | MTOR (1.00) | MTORPIK3CACYP3A4KCNH2RPTOR | |
| Rg-7603 SCHEMBL1831522 | 1.00 | MTOR (1.00) | MTORPIK3CACYP3A4KCNH2RPTOR | |
| Rg-7603 SCHEMBL1831520 | 1.00 | MTOR (1.00) | MTORPIK3CACYP3A4KCNH2RPTOR | |
| SCHEMBL2098645 | 0.95 | MTOR (0.91) | MTORPIK3CACYP3A4KCNH2RPTOR | |
| SCHEMBL1830460 | 0.95 | MTOR (0.91) | MTORPIK3CACYP3A4KCNH2RPTOR | |
| SCHEMBL1830931 | 0.95 | MTOR (0.91) | MTORPIK3CACYP3A4KCNH2RPTOR | |
| SCHEMBL2098648 | 0.95 | MTOR (0.91) | MTORPIK3CACYP3A4KCNH2RPTOR | |
| SCHEMBL1832032 | 0.94 | MTOR (1.00) | MTORPIK3CACYP3A4KCNH2RPTOR | |
| SCHEMBL1832036 | 0.94 | MTOR (1.00) | MTORPIK3CACYP3A4KCNH2RPTOR | |
| SCHEMBL1832580 | 0.94 | MTOR (0.91) | MTORPIK3CACYP3A4KCNH2RPTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 556 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729121-A2 | NOVEL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DERMAL DISORDERS | Drexel University (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260097038-A1 | COMPOSITIONS OF ADAGRASIB AND mTOR INHIBITORS AND METHODS OF TREATMENT THEREWITH | Mirati Therapeutics, Inc. (US) | 2026-04-09 | — | — | US | claimed |
| US-12576069-B2 | Compositions and methods for treating slow-flow vascular malformations | YALE UNIVERSITY (US) | 2026-03-17 | — | — | US | claimed |
| EP-4698175-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-02-25 | — | — | EP | claimed |
| US-12527795-B2 | Compositions of adagrasib and mTOR inhibitors and methods of treatment therewith | Mirati Therapeutics, Inc. (US) | 2026-01-20 | — | — | US | claimed |
| EP-3639854-B1 | MTOR-INHIBITOR-CONTAINING MEDICINE FOR TREATING OR PREVENTING FUCHS' ENDOTHELIAL CORNEAL DYSTROPHY | THE DOSHISHA (JP) | 2026-01-07 | — | — | EP | claimed |
| US-12509729-B2 | Compositions and methods for the diagnosis and treatment of lymphatic system disorders | THE CHILDREN'S HOSPTAL OF PHILADELPHIA (US) | 2025-12-30 | — | — | US | claimed |
| US-20250334588-A1 | TREATING TUBEROUS SCLEROSIS COMPLEX-ASSOCIATED DISEASES | UNITED STATES GOVERNMENT | 2025-10-30 | — | — | US | claimed |
| WO-2025217183-A1 | PREPARED NATURAL KILLER CELLS AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-10-16 | — | — | WO | claimed |
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| US-11433090-B2 | mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof | THE DOSHISHA (JP) | 2022-09-06 | — | — | US | claimed |
| US-11401553-B2 | Compositions and methods for the diagnosis and treatment of lymphatic system disorders | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2022-08-02 | — | — | US | claimed |
| CN-114790209-A | Optimized combinations and their use for the treatment of cancer and autoimmune diseases | 浙江导明医药科技有限公司 | 2022-07-26 | — | — | CN | claimed |
| US-20220218734-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING UVEAL MELANOMA | UNIV GENT (BE) | 2022-07-14 | — | — | US | claimed |
| EP-4013417-A1 | METHODS AND COMPOSITIONS FOR TREATING VASCULAR MALFORMATIONS | Deciphera Pharmaceuticals, LLC (US) | 2022-06-22 | — | — | EP | claimed |
| EP-4010081-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2022-06-15 | — | — | EP | claimed |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2022-04-07 | — | — | US | claimed |
| EP-3976055-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING UVEAL MELANOMA | Universiteit Gent (BE) | 2022-04-06 | — | — | EP | claimed |
| US-20220040182-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. | 2022-02-10 | — | — | US | claimed |
| US-20220031673-A1 | Novel Compositions and Methods for Treating or Preventing Dermal Disorders | UNIV DREXEL (US) | 2022-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527795-B2 | Compositions of adagrasib and mTOR inhibitors and methods of treatment therewith | KRAS, NRAS, HRAS | MTOR 19/4885PIK3CA 6/4885CYP3A4 4136/4885 |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | PNPLA2, LIPC, PNLIP | MTOR 3881/4885PIK3CA 1695/4885CYP3A4 2329/4885 |
| US-20260097038-A1 | COMPOSITIONS OF ADAGRASIB AND mTOR INHIBITORS AND METHODS OF TREATMENT THEREWITH | KRAS, NRAS, BRAF | MTOR 9/4885PIK3CA 15/4885CYP3A4 3352/4885 |
| US-20220031673-A1 | Novel Compositions and Methods for Treating or Preventing Dermal Disorders | MTOR, RPTOR, DEPTOR | MTOR 1/4885PIK3CA 64/4885CYP3A4 4883/4885 |
| US-12509729-B2 | Compositions and methods for the diagnosis and treatment of lymphatic system disorders | BTK, MTOR, ARAF | MTOR 2/4885PIK3CA 82/4885CYP3A4 4657/4885 |
| US-20220040182-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | MTOR 6/4885PIK3CA 9/4885CYP3A4 4177/4885 |
| US-12576069-B2 | Compositions and methods for treating slow-flow vascular malformations | RICTOR, MTOR, PIK3R5 | MTOR 2/4885PIK3CA 6/4885CYP3A4 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.